WOMEN'S HEALTH: Edited by Joseph AquilinaHaemorrhage at caesarean section: a framework for prevention and researchJardine, Jennifer E.a,b; Law, Pennyc; Hogg, Matthewa; Murphy, Deirdred; Khan, Khalid S.e; on behalf of C-SAFETYAuthor Information aRoyal London Hospital, Barts Health NHS Trust bWomen's Health Research Unit, Barts and the London School of Medicine, Queen Mary University of London cHillingdon Hospital, London, UK dDepartment of Obstetrics and Gynaecology, Trinity College, University of Dublin, Ireland eUniversity College London, London, UK Correspondence to Jennifer E. Jardine, Academic Clinical Fellow in Obstetrics and Gynaecology, Queen Mary University of London, London, UK. E-mail: [email protected] Current Opinion in Obstetrics and Gynecology: December 2016 - Volume 28 - Issue 6 - p 492-498 doi: 10.1097/GCO.0000000000000328 Buy Metrics Abstract Purpose of review Caesarean section rates are increasing across the world. Postpartum haemorrhage is a major cause of morbidity and mortality; major haemorrhage is more common after caesarean delivery. There is a wide range of practice in the prevention and treatment of postpartum haemorrhage at caesarean section. The aim of this review is to summarize current opinion in the management of postpartum haemorrhage at caesarean section. Recent findings Recent large randomized controlled trials have shown a possible effect from the routine use of tranexamic acid and ergometrine. Small randomized controlled trials have shown a possible benefit from using carbetocin. Summary The impact of postpartum haemorrhage can be reduced by antenatal correction of anaemia. Intraoperative medical management consists of oxytocinon, additional oxytocics +/− tranexamic acid, with at present limited evidence as to the order in which these should be considered. Trials of routine use of cell salvage and tranexamic acid are currently underway. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.